Concepts (115)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 16 | 2025 | 2771 | 1.210 |
Why?
|
| Methamphetamine | 1 | 2021 | 48 | 0.700 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2011 | 1317 | 0.640 |
Why?
|
| Receptors, CXCR4 | 5 | 2011 | 71 | 0.630 |
Why?
|
| Receptors, Estrogen | 9 | 2025 | 830 | 0.600 |
Why?
|
| Eukaryotic Initiation Factor-4E | 2 | 2009 | 55 | 0.570 |
Why?
|
| Designer Drugs | 1 | 2015 | 4 | 0.490 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2025 | 1357 | 0.460 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2015 | 149 | 0.450 |
Why?
|
| Psychotropic Drugs | 1 | 2015 | 130 | 0.450 |
Why?
|
| Receptor, ErbB-2 | 8 | 2025 | 562 | 0.380 |
Why?
|
| Piperazines | 2 | 2025 | 256 | 0.360 |
Why?
|
| Mastectomy, Modified Radical | 1 | 2010 | 5 | 0.350 |
Why?
|
| Inflammatory Breast Neoplasms | 1 | 2010 | 6 | 0.350 |
Why?
|
| Substance-Related Disorders | 1 | 2015 | 494 | 0.340 |
Why?
|
| Receptors, Progesterone | 8 | 2025 | 899 | 0.340 |
Why?
|
| Neoadjuvant Therapy | 3 | 2010 | 406 | 0.330 |
Why?
|
| Lymph Node Excision | 1 | 2010 | 176 | 0.320 |
Why?
|
| Neoplasm Metastasis | 1 | 2012 | 745 | 0.300 |
Why?
|
| Lymphatic Metastasis | 4 | 2012 | 452 | 0.290 |
Why?
|
| Biomarkers, Tumor | 4 | 2010 | 1721 | 0.290 |
Why?
|
| Disease-Free Survival | 7 | 2013 | 972 | 0.270 |
Why?
|
| Pyridines | 1 | 2025 | 251 | 0.210 |
Why?
|
| Kaplan-Meier Estimate | 7 | 2025 | 1144 | 0.210 |
Why?
|
| Chemotherapy, Adjuvant | 4 | 2010 | 401 | 0.210 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2010 | 170 | 0.200 |
Why?
|
| Craving | 1 | 2021 | 15 | 0.190 |
Why?
|
| Middle Aged | 16 | 2025 | 29430 | 0.180 |
Why?
|
| Mastectomy | 4 | 2010 | 82 | 0.180 |
Why?
|
| Neoplasm Staging | 4 | 2012 | 1391 | 0.180 |
Why?
|
| Antineoplastic Agents | 3 | 2025 | 1854 | 0.160 |
Why?
|
| Positron-Emission Tomography | 2 | 2012 | 312 | 0.150 |
Why?
|
| Combined Modality Therapy | 5 | 2010 | 1312 | 0.150 |
Why?
|
| Survival Analysis | 4 | 2013 | 1595 | 0.150 |
Why?
|
| Survival Rate | 3 | 2012 | 2214 | 0.130 |
Why?
|
| Female | 18 | 2025 | 72054 | 0.130 |
Why?
|
| Humans | 20 | 2025 | 134225 | 0.130 |
Why?
|
| Short Bowel Syndrome | 1 | 2016 | 66 | 0.130 |
Why?
|
| Prospective Studies | 7 | 2016 | 6617 | 0.120 |
Why?
|
| Aromatase Inhibitors | 2 | 2025 | 79 | 0.120 |
Why?
|
| Enteral Nutrition | 1 | 2016 | 267 | 0.110 |
Why?
|
| Prognosis | 6 | 2013 | 5085 | 0.110 |
Why?
|
| Predictive Value of Tests | 4 | 2010 | 2319 | 0.110 |
Why?
|
| Aged | 8 | 2025 | 21822 | 0.100 |
Why?
|
| Mammography | 2 | 2013 | 133 | 0.100 |
Why?
|
| Proportional Hazards Models | 3 | 2013 | 1486 | 0.100 |
Why?
|
| Adult | 9 | 2025 | 31962 | 0.100 |
Why?
|
| Peptides | 1 | 2016 | 864 | 0.100 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2010 | 2137 | 0.100 |
Why?
|
| Aged, 80 and over | 5 | 2013 | 7244 | 0.100 |
Why?
|
| Follow-Up Studies | 4 | 2016 | 5466 | 0.090 |
Why?
|
| Calcinosis | 1 | 2013 | 192 | 0.090 |
Why?
|
| Databases, Factual | 4 | 2025 | 1260 | 0.090 |
Why?
|
| Radiography, Thoracic | 1 | 2012 | 153 | 0.090 |
Why?
|
| Mastitis | 1 | 2010 | 3 | 0.090 |
Why?
|
| Treatment Outcome | 7 | 2025 | 13105 | 0.090 |
Why?
|
| Axilla | 1 | 2010 | 44 | 0.090 |
Why?
|
| Contraindications | 1 | 2010 | 77 | 0.090 |
Why?
|
| Ultrasonography, Mammary | 1 | 2010 | 33 | 0.090 |
Why?
|
| Retrospective Studies | 6 | 2025 | 17591 | 0.080 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2010 | 71 | 0.080 |
Why?
|
| Mastectomy, Segmental | 1 | 2010 | 40 | 0.080 |
Why?
|
| Socioeconomic Factors | 2 | 2010 | 920 | 0.080 |
Why?
|
| Risk Assessment | 3 | 2016 | 3754 | 0.080 |
Why?
|
| Hospitals, Public | 1 | 2009 | 44 | 0.080 |
Why?
|
| Drug Monitoring | 1 | 2010 | 185 | 0.070 |
Why?
|
| Academic Medical Centers | 1 | 2009 | 334 | 0.070 |
Why?
|
| Body Mass Index | 1 | 2013 | 1722 | 0.060 |
Why?
|
| Palliative Care | 1 | 2010 | 464 | 0.060 |
Why?
|
| Androstadienes | 1 | 2006 | 52 | 0.060 |
Why?
|
| Kidney Failure, Chronic | 1 | 2013 | 906 | 0.060 |
Why?
|
| Carcinoma | 1 | 2008 | 321 | 0.060 |
Why?
|
| Treatment Failure | 1 | 2006 | 365 | 0.060 |
Why?
|
| Nitriles | 1 | 2006 | 155 | 0.060 |
Why?
|
| Postmenopause | 1 | 2006 | 155 | 0.060 |
Why?
|
| Triazoles | 1 | 2006 | 142 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2010 | 1982 | 0.060 |
Why?
|
| Age Factors | 2 | 2016 | 2997 | 0.060 |
Why?
|
| Probability | 1 | 2005 | 334 | 0.060 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2013 | 808 | 0.060 |
Why?
|
| Tamoxifen | 1 | 2006 | 377 | 0.050 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2006 | 271 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2012 | 2204 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2010 | 5225 | 0.050 |
Why?
|
| Neoplasm Proteins | 1 | 2008 | 719 | 0.050 |
Why?
|
| Obesity | 1 | 2013 | 2449 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2006 | 1222 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2010 | 3869 | 0.040 |
Why?
|
| HeLa Cells | 2 | 2010 | 840 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 753 | 0.030 |
Why?
|
| Genes, erbB-2 | 1 | 2013 | 38 | 0.030 |
Why?
|
| Thinness | 1 | 2013 | 77 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 1735 | 0.020 |
Why?
|
| Sex Factors | 1 | 2016 | 1388 | 0.020 |
Why?
|
| Morbidity | 1 | 2013 | 256 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 308 | 0.020 |
Why?
|
| Patient Safety | 1 | 2016 | 436 | 0.020 |
Why?
|
| Risk Factors | 3 | 2013 | 11196 | 0.020 |
Why?
|
| Disease Progression | 2 | 2008 | 2265 | 0.020 |
Why?
|
| Mastectomy, Radical | 1 | 2010 | 9 | 0.020 |
Why?
|
| Overweight | 1 | 2013 | 387 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2013 | 543 | 0.020 |
Why?
|
| Louisiana | 1 | 2009 | 137 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 3119 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2010 | 1138 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2009 | 677 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2008 | 303 | 0.020 |
Why?
|
| Poverty | 1 | 2009 | 438 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2008 | 426 | 0.020 |
Why?
|
| Risk | 1 | 2008 | 833 | 0.020 |
Why?
|
| Incidence | 1 | 2013 | 3424 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2016 | 14897 | 0.010 |
Why?
|
| Adolescent | 1 | 2016 | 20647 | 0.010 |
Why?
|
| Child | 1 | 2016 | 25917 | 0.010 |
Why?
|
| Male | 1 | 2016 | 66215 | 0.010 |
Why?
|